China's API Industry Enters Strategic Breakthrough Phase Amid Global Supply Chain Restructuring

As the global pharmaceutical supply chain undergoes profound restructuring, China's active pharmaceutical ingredients (API) sector is navigating a pivotal transition. Moving beyond the former period of fierce price-driven competition, the industry is now entering a 'value war' phase, demonstrating renewed resilience and emerging growth momentum.

1. Sector Bottoms Out and Rebounds, Revealing Strong Growth Resilience

Following a brief adjustment in 2023 caused by global destocking and intensified competition, China's API industry has shown clear signs of recovery in 2024–2025.

In 2024, industry revenue stabilised at RMB 424.15 billion, achieving a positive growth rate of 0.3%, signalling the close of the adjustment cycle. Strengthened resilience continued into 2025: during the first half, revenue and profit increased by 1.5% and 5.6% respectively, with profit growth significantly outpacing revenue, reflecting improved profitability.

From January to September 2025, cumulative production of chemical drug substances reached 2.721 million tonnes, up 1.2% year-on-year. Despite occasional monthly fluctuations, overall operations returned to a reasonable range, laying a foundation for stable development.

2. Deep Structural Differentiation: Transition from 'Broad and Comprehensive' to 'Specialised and Sophisticated'

The industry has moved beyond extensive expansion and evolved into a distinct three-tier pyramid structure, each with unique competitive characteristics.

• Base Tier — Bulk APIs

Dominated by antibiotics, vitamins, and antipyretic analgesics, this segment features highly concentrated capacity and strong cyclical pricing. Competitiveness is driven by scale and cost advantages, where China retains long-standing strengths.

• Middle Tier — Speciality APIs

Focused on cardiovascular, diabetes, and oncology markets, this segment possesses higher technical barriers and greater value-added potential. Companies such as Huahai and Tianyu have successfully shifted from bulk products to speciality APIs, establishing a presence in high-end international markets.

• Apex Tier — Patented APIs (CDMO)

The fastest-growing segment, directly supporting global innovative drug R&D. With increasing outsourcing demand, this sector is projected to exceed 15% growth by 2025. Leading enterprises including WuXi AppTec and Asymchem have secured high-end global contracts and integrated into advanced innovation ecosystems.

3. Competitive Landscape Divides into Three Distinct Strategic Camps

Structural transformation has prompted enterprises to pursue differentiated strategies, forming three clear competitive camps.

• Full-Chain Giants

Represented by Huahai Pharmaceutical and Apeloa, these firms have developed vertically integrated systems from APIs to finished dosage forms. Their strengths lie in industrial synergy, cost optimisation, supply chain security, and internationally certified quality systems (e.g., FDA compliance) that support global expansion.

• Niche Market Champions

Avoiding direct competition with large players, these companies excel through specialisation. Jiuzhou Pharmaceutical has built deep partnerships in small-molecule CDMO services, while SINOPEP and ShengNuo Biology have capitalised on the GLP-1 weight-loss drug trend, becoming core peptide API suppliers. Their competitive advantage stems from specialised expertise and irreplaceable customer relationships.

• Technological Frontier Pioneers

Companies such as Aurisco and Porton advance platforms in emerging fields including small nucleic acids and continuous flow synthesis, seeking breakthroughs through technological generation gaps to gain advantage in the next industry cycle.

4. Foreign Trade Transformation: Shifting from Low-Price Volume to High-Value Growth

Import–export data reflects improving competitiveness. From January to September 2025, China's total API import–export value reached US$41.55 billion, up 4.7% year-on-year, indicating a positive trend.

A key inflection point emerged: the two-year strategy of sacrificing margins for export volume ended in early 2025, with export prices rising 0.5% year-on-year, signalling a shift from low-cost competition to quality and technology-led expansion.

Export performance varied across product categories:

• Vitamin exports grew sharply (vitamin E up 68.0%) amid overseas supply constraints.

• Hormone exports increased 21.8% on strong global demand.

• Antibiotic exports declined 9.1% due to weak demand, with notable internal structural divergence.

Asia and Europe accounted for 74% of total exports, with India and the United States remaining the largest individual markets.

However, import patterns revealed weaknesses: in the first half of 2025, China's API imports from Denmark surged 27.8%, reinforcing Denmark's position as the largest supplier due to its advanced biopharmaceutical technologies. This highlights China's ongoing reliance on imported high-value patented APIs and biologics, representing a critical challenge for future development.

Outlook

China's API industry is transitioning from a 'fine brushwork' focus on scale to a 'freehand painting' emphasis on structure, technology, and value. The end of the adjustment period signals not a return to past models, but the beginning of a new phase marked by intensified differentiation and accelerated market consolidation.

Future success will favour enterprises that achieve precise positioning—whether by building full-chain ecosystems, excelling in strategic niches, or pioneering breakthrough technologies. At the same time, overcoming deficiencies in high-value patented APIs will be essential for the transition from a large-scale producer to a global power in the API sector.